Welcome to our dedicated page for Brainstorm Cell Therapeutics I SEC filings (Ticker: BCLI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BrainStorm Cell Therapeutics Inc. (BCLI) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Forms 10-K, 10-Q, 8-K, and specialized documents such as Form 25. These filings offer detailed information on BrainStorm’s NurOwn® clinical programs, financing arrangements, equity plans, and listing status.
Recent Form 8-K reports describe material events such as the issuance of promissory and convertible promissory notes to institutional investors, with terms covering original issue discounts, maturity dates, amortization schedules, and potential conversion into common stock subject to beneficial ownership limits. Other 8-K filings document shareholder approvals to increase the share pool under the 2014 Stock Incentive Plan and 2014 Global Share Option Plan, as well as the results of annual meetings.
A Form 25 filed on October 9, 2025 by The Nasdaq Stock Market LLC formally records the removal of BrainStorm Cell Therapeutics Inc.’s common stock from listing and registration on Nasdaq. Subsequent 8-Ks and press releases indicate that BCLI is quoted on the OTCQB Venture Market. These documents are important for understanding changes in trading venue and related compliance considerations.
Investors can also use BrainStorm’s periodic reports to review clinical development disclosures for NurOwn in ALS and progressive multiple sclerosis, as well as information on the company’s allogeneic exosome-based platform. Filings often reference regulatory milestones such as Orphan Drug designations, Special Protocol Assessment agreements, and FDA clearances for clinical trials.
On Stock Titan, each filing is accompanied by AI-powered summaries that highlight key terms, risk factors, financing structures, and clinical or regulatory updates, helping readers navigate complex documents more efficiently. Users can quickly locate quarterly reports (10-Q), annual reports (10-K), current reports on Form 8-K, and any available insider-related filings such as Form 4, while the AI summaries point out provisions that may affect dilution, capital structure, or the status of BrainStorm’s NurOwn and exosome programs.
Brainstorm Cell Therapeutics Inc. (Nasdaq: BCLI) has filed a Form S-3 shelf registration statement dated June 25, 2025. The filing registers up to 2,762,766 shares of common stock that may be resold from time to time by a single Selling Stockholder. The shares correspond to an equal number of common stock purchase warrants (designated “Inducement Warrants”) issued in a private placement on April 1, 2025. These warrants carry a cash exercise price of $1.19 per share, marginally below the June 24, 2025 closing price of $1.23.
The company itself will not sell shares nor receive proceeds from any secondary sales. It will, however, receive up to $3.29 million of gross proceeds if the Selling Stockholder elects to exercise all warrants in cash. Management states that any such proceeds would be used for working capital and general corporate purposes.
Key structural details include: (i) filing made under Rule 415 allowing continuous or delayed resales; (ii) BCLI is classified as a non-accelerated filer and smaller reporting company; (iii) no automatic effectiveness—statement will become effective only upon SEC approval; and (iv) no additional securities beyond those underlying the Inducement Warrants are being registered.
Potential investor considerations appear in the prospectus: dilution risk from warrant conversion, possible market overhang from discretionary resale by the Selling Stockholder, and limited capital inflow tied solely to warrant exercise. The prospectus addresses standard sections such as Risk Factors, Plan of Distribution, and Use of Proceeds but does not include financial statements or earnings data in this portion of the filing.
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) filed a Form 8-K summarizing the results of its June 25, 2025 virtual Annual Meeting of Stockholders. Shareholders approved Amendment No. 5 to both the 2014 Stock Incentive Plan and the 2014 Global Share Option Plan, expanding the shared equity pool by 2,000,000 shares to a total of 2,906,666 shares. Company officers and directors remain eligible to receive awards under the enlarged pool.
All seven director nominees—Dr. Irit Arbel, Dr. Menghisteab Bairu, Dr. Jacob Frenkel, Nir Naor, Dr. Anthony Polverino, Uri Yablonka and Dr. Stacy Lindborg—were re-elected, with votes “FOR” ranging from 958,146 to 1,055,967 and 2,556,446 broker non-votes on each slate. Shareholders also ratified Deloitte-affiliate Brightman Almagor Zohar & Co. as independent auditor for FY-2025 (3,346,891 “FOR” versus 315,162 “AGAINST”).
In addition, investors approved (i) Nasdaq Rule 5635(d) clearance to issue shares underlying a Common Warrant potentially exceeding 20% of current outstanding shares (874,965 “FOR”) and (ii) the aforementioned share-reserve increase (758,668 “FOR”, 362,809 “AGAINST”). No financial statements were presented; the filing is limited to governance and equity-compensation matters. The new equity authorizations could be dilutive if fully exercised, but they provide the company with added flexibility to reward personnel and fund future growth initiatives.